Zevalin Therapy

You have been scheduled for a zevalin therapy. Zevalin is used to treat CD20 positive non-Hodgkin’s lymphoma. The Zevalin regimen combines a monoclonal antibody directed against the CD20 antigen with the radioisotope yttrium-90 (Y-90).

Preparation for the procedure:
You will have a Rituximab infusion at your Oncologist office within four hours prior to coming to the Cancer Center for your Zevalin therapy. Please inform the technologist if you are pregnant or breast feeding. This treatment is not recommended for women who are pregnant or breastfeeding.

What to expect:
Visit 1: Within four hours following your Rituximab infusion at your Oncologist’s office you will come to the Cancer Center where you will be brought to an exam room. You will then be given an infusion of In-111 Zevalin over a ten minute period.
Visit 2: The second or third day following the infusion you will return for images on a gamma camera.
Visit 3: The following week (seven days from the first infusion) begins the treatment portion. Within four hours following your Rituximab infusion at your Oncologist’s office you will come to the Cancer Center where you will be brought to an exam room. You will then be given an infusion of Y-90 Zevalin over a ten minute period. There are no special precautions that need to be followed after the treatment.

The follow up for your care will continue to be provided by your own Oncologist.

Your questions and comments:
call (805) 563-5870.

Back to list